(Reuters) – Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company’s renal cancer drug candidate.
The company’s lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.
Peloton shareholders will be eligible to receive a further $1.15 billion on achieving certain milestones.
The company had been looking to go public and gave a pricing range of $15 to $17 per share for its initial public offering last week.
Credit Suisse acted as financial adviser for Merck and Covington & Burling LLP as its legal adviser. Centerview Partners was financial adviser to Peloton and Wilson Sonsini Goodrich & Rosati was its legal adviser.
F.P. Report KARACHI: Pakistani health authorities vaccinated over seven million, or 24.9% of the targeted…
(AFP): More than one in every 100 deaths globally is due to suicide, the World…
SYDNEY (AFP): An Australian state has banned plastic fish-shaped soy sauce containers, reeling in a…
F.P. Report World Athletics Champion Arshad Nadeem obtained a Japanese visa for participation in the…
WASHINGTON (Reuters) : Microsoft has agreed to give US agencies a discount on its cloud…
F.P. Report ISLAMABAD: Monsoon rains and flooding have claimed 18 more lives and left 29…
This website uses cookies.